Neuronetics this week added an underwriter’s option to its initial public offering, which could bring in between $10.5 million and $12 million if fully exercised, and gave a rough price range for the offering.
The Malvern, Penn.-based company said it is filing for the public offering to expand its commercialization efforts for the NeuroStar transcranial magnetic stimulation device for treating depression.
Neuronetics now plans to offer a total of 5 million shares up front, expecting them to be priced between $14 and $16 per share, which would bring the total for the IPO to between $70 million and $80 million.
The over-allotment option, which adds an additional 750,000 shares, lifts the total the company could raise up to a maximum of $92 million, according to a recently posted SEC filing. Neuronetics said it plans to list its shares on the NASDAQ exchange under the “STIM” symbol.
The company’s NeuroStar device uses MRI-strength magnetic fields to stimulate specific areas of the brain associated with mood. The device initially won 510(k) clearance from the FDA in December 2008, for treating adults with major depressive disorder who previously failed to respond to one medication. The federal safety watchdog expanded NeuroStar’s indication in May 2014 to cover adult patients who failed to respond to one or more medications in their current depressive episode.
There are 781 NeuroStar installations across 615 psychiatry practices, with some 50,000 patients treated in roughly 1.8 million sessions, the company said in its SEC filing. The company reported losses last year of -$16.1 million, or -$2.97 per share, on sales of $40.4 million, increased its red ink by 42.9% on sales growth of 18.1% compared with 2016.
First-quarter losses grew 21.8% to -$5.5 million, or -84¢ per share, on sales of $10.2 million for the three months ended March 31, for a top-line gain of 34.9% compared with Q1 2017.
The company registered for the IPO earlier this month, with Piper Jaffray and William Blair & Co. maned as joint book-runners and Canaccord Genuity and JMP Securities as co-managers.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.